Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Exclusion Criteria

• •Autologous HSCT.
• •Receipt of donor lymphocyte infusions during the 28 days preceding enrollment.
• •Uncontrolled GVHD that in the opinion of the investigator would prevent the subject from participating in the study.
• •Lansky/Karnofsky Score \<=60%.
• •Receipt of plasma products or immunoglobulins during the 60 days preceding enrollment.
• •Receipt of rituximab since HSCT.
• •Receipt of chemotherapy for relapse of underlying malignant disease since HSCT.
• •Human immunodeficiency virus (HIV) infection.
• •Lymphoproliferative disorder since HSCT.
• •Chronic illnesses with cardiac, pulmonary, renal, or liver failure that in the opinion of the investigator would prevent the subject participating in the study.
• •Vaccination with any licensed or experimental pneumococcal vaccine since HSCT.
• •Previous anaphylactic reaction to any vaccine or vaccine-related component.
• •Bleeding diathesis or condition associated with prolonged bleeding time that would in the opinion of the investigator contraindicate intramuscular injection.
• •Participation in another study with ongoing use of an unlicensed investigational product from 28 days before study enrollment until the end of the study.
• •Participation in another study with ongoing use of a licensed investigational product that in the opinion of the investigator would interfere with the evaluation of the study objectives.
• •Permanent residence in a nursing home or other residential care facility.
• •Pregnant or breastfeeding female subject.
• •Subject who is a direct relative (child, grandchild, parent, or grandparent) of study personnel, or is a member of the study personnel.
• •Receipt of advanced therapy medicinal products (ATMP) including gene therapy products, somatic cell therapy products, and tissue engineered products at any time before enrollment.
• •If information is available, - previous allergic or anaphylactic reaction to any vaccine or vaccine-related component in a stem cell donor.